As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development, and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies' success. We realize that our strength and competitive advantage lie with our people. We support our employees in several ways to foster a healthy working environment, meaningful work, diversity and inclusion, mobility, networking, and work-life balance. Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees.
The Executive Director, Early Asset TA Lead is a pivotal role responsible for alignment of the strategic direction of global early asset programs to optimize success for US patients and stakeholders. This role is responsible for leading the cross-functional US early assets TA team (Medicine and Value & Access) and Clinical Development role(s) within their assigned TA. The US Early Assets TA lead possesses broad expertise in the science of clinical development, and familiarity with the unique evidence generation needs of US regulatory, payer, and health systems customers. They also have extensive experience navigating the US legal and compliance landscape within a pharmaceutical environment. They leverage this expertise – together with their leadership and influencing skills – to co-create early asset strategies with global Early Asset teams to ensure the strategic direction of these programs optimize product approval, clinical adoption, product access and competitiveness in the US.
As the accountable point of contact for global early asset teams in the US, the US Early Assets TA Lead leverages exceptional advocacy, communication, and negotiation skills to co-create strategies with the global Early Asset teams, ensuring that US-specific considerations are prioritized and implemented in the strategic and tactical planning for early assets. The ED, Early Asset TA Lead will be required to engage with the most senior US and global TA Leadership to proactively raise and mitigate strategic issues, as well as advocate for US needs in development plans. The incumbent inspires the collective early assets team to consider the patient first and foremost and drives holistic, innovative solutions that serve the unique needs of patients.
Duties & Responsibilities Inspires and challenges the cross-functional Early Assets TA team, together with integration and deliverable teams, to design innovative approaches that are fit-for-purpose for US patients and market needs.Actively solicits team expertise and input in the early asset development programs and deliverables (e.g., early TPP, AEP, Integrated Evidence Plan, etc.)Serves as challenge partner to integration and/or deliverable teams as appropriate to ensure alignment on strategy.Manages critical interfaces across Value & Access and Medicine to ensure cohesive cross-functional planning and execution.Responsible for smart risk taking and smart risk management, ensuring inclusion of legal and compliance representatives in decision-making as appropriate.Manages Clinical Development roles within their assigned TA.
Early Assets Development Leadership:
Global Collaboration
Planning:
Eligibility Requirements:
This position offers a base salary typically between $184,000 and $325,000. The position may be eligible for a role specific variable or performance based bonus and or other compensation elements. For an overview of our benefits please click here.